Taylor Moore
Family · New Castle, INNPI 1447704291
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $600, 2.2 times the $269 reported in 2022.
Across 125 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$418
- Novo Nordisk$223
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$168
- Lilly USA, LLC$161
- Boehringer Ingelheim$108
- Otsuka America Pharmaceutical, Inc.$94
- plus $792 from 20 others
What the payments were for
- Food & beverage$1,963100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $418 |
| Novo Nordisk | 13 | $223 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $168 |
| Lilly USA, LLC | 10 | $161 |
| Boehringer Ingelheim | 7 | $108 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| Pfizer | 5 | $72 |
| Astellas Pharma US Inc | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $63 |
| Exact Sciences | 4 | $61 |
| Novartis | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $50 |
| Axsome Therapeutics, Inc. | 3 | $49 |
| Bayer | 3 | $48 |
| GSK | 3 | $47 |
| Lundbeck LLC | 3 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Corium, LLC | 3 | $40 |
| Amgen | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| Abbott | 1 | $19 |
| AstraZeneca | 1 | $17 |
| Medtronic | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Biogen | 1 | $15 |
| Boston Scientific | 1 | $14 |
How this compares
$1,963 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $132,847 |
| TrulicityDulaglutide | 23 | $33,139 |
| JardianceEmpagliflozin | 26 | $29,920 |
| MounjaroTirzepatide | 23 | $23,928 |
| EliquisApixaban | 20 | $17,448 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $16,546 |
| Spiriva RespimatTiotropium Bromide | 16 | $11,960 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,771 |
| Praluent PenAlirocumab | 12 | $5,962 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 138 | $3,609 |
| Duloxetine Hcl | 142 | $3,471 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,840 |
| Potassium Chloride | 30 | $2,211 |
| Buspirone Hcl | 101 | $1,715 |
| Atorvastatin Calcium | 140 | $1,287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $223 | $132,847127 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $161 | $57,06746 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $108 | $41,87942 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $47 | $23,31743 claims |
| PfizerEliquis | $72 | $17,44820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.
Other family in New Castle
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.